CN-201

DB18726InvestigationalProtein Based Therapies

CN-201 is a humanized anti-CD3/CD19 bispecific antibody.

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: recombinant humanized anti-CD3/CD19 bispecific antibody
Code names: CN-201

Resolves to

Targets

What you can answer from here — as of July 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with CN-201, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.